Cardiff Oncology IncNASDAQ:CRDF
- LAST PRICE3.2300
- TODAY'S CHANGE (%)-0.2100 (-6.1047%)
- Bid / Lots3.2300/ 8
- Ask / Lots3.2500/ 8
- Open / Previous Close3.4400 / 3.4400
- Day Range
- 52 Week Range
- Volume236,135
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRDF |
|---|---|---|
| 09:32 ET | 6959 | 3.4 |
| 09:34 ET | 38447 | 3.41 |
| 09:36 ET | 600 | 3.4225 |
| 09:38 ET | 5000 | 3.43 |
| 09:41 ET | 300 | 3.3922 |
| 09:43 ET | 446 | 3.39 |
| 09:45 ET | 1200 | 3.35 |
| 09:48 ET | 1075 | 3.355 |
| 09:50 ET | 300 | 3.3433 |
| 09:52 ET | 2327 | 3.3641 |
| 09:54 ET | 300 | 3.35 |
| 09:56 ET | 200 | 3.35 |
| 09:57 ET | 2369 | 3.31 |
| 09:59 ET | 13925 | 3.31 |
| 10:01 ET | 1000 | 3.31 |
| 10:03 ET | 1650 | 3.32 |
| 10:06 ET | 200 | 3.28 |
| 10:08 ET | 600 | 3.28 |
| 10:12 ET | 3070 | 3.31 |
| 10:14 ET | 2020 | 3.3 |
| 10:15 ET | 1900 | 3.29 |
| 10:17 ET | 620 | 3.2998 |
| 10:19 ET | 2200 | 3.29 |
| 10:21 ET | 11902 | 3.31 |
| 10:24 ET | 12090 | 3.3148 |
| 10:26 ET | 6358 | 3.31 |
| 10:28 ET | 11187 | 3.3 |
| 10:30 ET | 8636 | 3.27 |
| 10:32 ET | 2537 | 3.269 |
| 10:33 ET | 1710 | 3.27 |
| 10:35 ET | 500 | 3.27 |
| 10:37 ET | 1300 | 3.28 |
| 10:39 ET | 2164 | 3.27 |
| 10:42 ET | 2200 | 3.2701 |
| 10:44 ET | 1300 | 3.27 |
| 10:46 ET | 800 | 3.26 |
| 10:48 ET | 600 | 3.27 |
| 10:50 ET | 788 | 3.275 |
| 10:51 ET | 900 | 3.275 |
| 10:53 ET | 3556 | 3.27 |
| 10:55 ET | 1309 | 3.265 |
| 10:57 ET | 100 | 3.265 |
| 11:00 ET | 1950 | 3.265 |
| 11:02 ET | 1555 | 3.27 |
| 11:04 ET | 800 | 3.27 |
| 11:06 ET | 100 | 3.27 |
| 11:08 ET | 200 | 3.26 |
| 11:09 ET | 921 | 3.26 |
| 11:13 ET | 2182 | 3.2501 |
| 11:15 ET | 300 | 3.25 |
| 11:18 ET | 2296 | 3.26 |
| 11:20 ET | 838 | 3.28 |
| 11:24 ET | 1358 | 3.29 |
| 11:26 ET | 1100 | 3.29 |
| 11:29 ET | 526 | 3.2824 |
| 11:31 ET | 3500 | 3.28 |
| 11:33 ET | 100 | 3.3 |
| 11:38 ET | 300 | 3.28 |
| 11:40 ET | 17636 | 3.26 |
| 11:42 ET | 100 | 3.26 |
| 11:44 ET | 15514 | 3.24 |
| 11:45 ET | 4215 | 3.2203 |
| 11:47 ET | 2215 | 3.225 |
| 11:49 ET | 553 | 3.22 |
| 11:51 ET | 3665 | 3.23 |
| 11:58 ET | 1856 | 3.2399 |
| 12:00 ET | 100 | 3.245 |
| 12:02 ET | 100 | 3.23 |
May 13, 2024
Cardiff Oncology to Present at Upcoming Investor Conferences in May, from 4:05PM ET on Monday May 13, 2024 by Dow Jones
4:05PM ET on Monday May 13, 2024 by Dow Jones
May 6, 2024
DJ Cardiff Oncology Price Target Maintained With a $14.00/Share by HC Wainwright & Co., from 6:38AM ET on Monday May 06, 2024 by Dow Jones
6:38AM ET on Monday May 06, 2024 by Dow Jones
May 2, 2024
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update, from 4:05PM ET on Thursday May 02, 2024 by Dow Jones
4:05PM ET on Thursday May 02, 2024 by Dow Jones*DJ Cardiff Oncology 1Q Loss/Shr 22c >CRDF, from 4:05PM ET on Thursday May 02, 2024 by Dow Jones
4:05PM ET on Thursday May 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cardiff Oncology Inc | 153.9M | -3.6x | --- |
X4 Pharmaceuticals Inc | 151.7M | -1.4x | --- |
Context Therapeutics Inc | 150.0M | -1.5x | --- |
Sagimet Biosciences Inc | 153.8M | -4.2x | --- |
Kodiak Sciences Inc | 161.3M | -0.7x | --- |
RAPT Therapeutics Inc | 145.5M | -1.4x | --- |
Company Information
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Contact Information
- Headquarters
- 11055 Flintkote AveSAN DIEGO, CA, United States 92121-1220
- Phone
- 858-952-7570
- Fax
- 858-217-4768
Executives
- Independent Chairman of the Board
- Rodney Markin
- Chief Executive Officer, Director
- Mark Erlander
- Chief Financial Officer
- James Levine
- Chief Operating Officer
- Vicki Kelemen
- Chief Scientific Officer
- Tod Smeal
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $153.9M |
|---|---|
Revenue (TTM) | $610.0K |
Shares Outstanding | 44.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.88 |
EPS | $-0.90 |
Book Value | $1.56 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | 252.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -7,261.15% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
